These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24837467)

  • 1. Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis.
    Lippert E; Mansier O; Migeon M; Denys B; Nilsson A; Rosmond C; Lodé L; Ugo V; Lascaux A; Bellosillo B; Martinez-Lopez J; Naguib D; Gachard N; Maroc N; Hermouet S
    Haematologica; 2014 Jul; 99(7):e98-101. PubMed ID: 24837467
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms.
    Hu L; Pu L; Ding Y; Li M; Cabanero M; Xie J; Zhou D; Yang D; Zhang C; Wang H; Zhai Z; Ru X; Li J; Xiong S
    Hematology; 2017 Jul; 22(6):354-360. PubMed ID: 27976991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.
    Edahiro Y; Morishita S; Takahashi K; Hironaka Y; Yahata Y; Sunami Y; Shirane S; Tsutsui M; Noguchi M; Koike M; Imai K; Kirito K; Noda N; Sekiguchi Y; Tsuneda S; Ohsaka A; Araki M; Komatsu N
    Int J Hematol; 2014; 99(5):625-34. PubMed ID: 24677207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms.
    Wang J; Xu Z; Liu L; Gale RP; Cross NC; Jones AV; Qin T; Ai X; Xu J; Zhang T; Sun X; Li Q; Zhang P; Zhang Y; Xiao Z
    Leukemia; 2013 Aug; 27(8):1763-7. PubMed ID: 23337930
    [No Abstract]   [Full Text] [Related]  

  • 5. JAK2V617F mutation in patients with splanchnic vein thrombosis.
    Xavier SG; Gadelha T; Pimenta G; Eugenio AM; Ribeiro DD; Gomes FM; Bonamino M; Zalcberg IR; Spector N
    Dig Dis Sci; 2010 Jun; 55(6):1770-7. PubMed ID: 19690956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel, highly sensitive and rapid allele-specific loop-mediated amplification assay for the detection of the JAK2V617F mutation in chronic myeloproliferative neoplasms.
    Minnucci G; Amicarelli G; Salmoiraghi S; Spinelli O; Guinea Montalvo ML; Giussani U; Adlerstein D; Rambaldi A
    Haematologica; 2012 Sep; 97(9):1394-400. PubMed ID: 22315499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate.
    Nielsen C; Bojesen SE; Nordestgaard BG; Kofoed KF; Birgens HS
    Haematologica; 2014 Sep; 99(9):1448-55. PubMed ID: 24907356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of the JAK2V617F mutation with the Ipsogen MutaScreen kit: absence of JAK2V617F does not mean absence of myeloproliferative neoplasm.
    Peyro-Saint-Paul H; Hermitte F
    Blood; 2010 Sep; 116(11):1994-5. PubMed ID: 20847214
    [No Abstract]   [Full Text] [Related]  

  • 9. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
    Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
    Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2V617F allele burden in patients with myeloproliferative neoplasms carrying Trisomy 9, and its relationship with clinical phenotypes.
    Li M; Wen L; Cen J; Feng Y; Chen S
    Int J Hematol; 2016 May; 103(5):599-601. PubMed ID: 27084251
    [No Abstract]   [Full Text] [Related]  

  • 11. The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.
    Perricone M; Polverelli N; Martinelli G; Catani L; Ottaviani E; Zuffa E; Franchini E; Dizdari A; Forte D; Sabattini E; Cavo M; Vianelli N; Palandri F
    Oncotarget; 2017 Jun; 8(23):37239-37249. PubMed ID: 28422729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
    Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
    Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte whole exome sequencing and endothelial JAK2V617F in patients with JAK2V617F positive Budd-Chiari Syndrome without myeloproliferative neoplasm.
    Helman R; Pereira WO; Marti LC; Campregher PV; Puga RD; Hamerschlak N; Chiattone CS; Santos FPS
    Br J Haematol; 2018 Feb; 180(3):443-445. PubMed ID: 27650062
    [No Abstract]   [Full Text] [Related]  

  • 14. [Relationship between TET2 Gene SNP rs3733609 C/T and JAK2V617F Allele Burden in Patients with Myeloproliferative Neoplasms].
    Xiao X; Liu XL; Shen XH; Deng MY; Liu SF; Zhang GS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1574-1579. PubMed ID: 31607314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of JAK2V617F mutation rate by real-time fluorescent quantitative PCR using allele specific primer and TaqMan-MGB probe for dual inhibiting amplification of wild type alleles].
    Liang GW; Shao DH; He ML; Cao QY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1486-91. PubMed ID: 23257459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.
    Dentali F; Squizzato A; Brivio L; Appio L; Campiotti L; Crowther M; Grandi AM; Ageno W
    Blood; 2009 May; 113(22):5617-23. PubMed ID: 19273837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 (V617F) and JAK2 exon 12 allele burden disappearance during the follow-up of two patients.
    Mahé K; Luque Paz D; Couturier MA; Chauveau A; Quintin-Roué I; Berthou C; Ugo V; Lippert E; Ianotto JC
    Ann Hematol; 2016 Feb; 95(3):529-31. PubMed ID: 26611851
    [No Abstract]   [Full Text] [Related]  

  • 18. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
    Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
    Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melting curve analysis after T allele enrichment (MelcaTle) as a highly sensitive and reliable method for detecting the JAK2V617F mutation.
    Morishita S; Takahashi K; Araki M; Hironaka Y; Sunami Y; Edahiro Y; Tsutsui M; Ohsaka A; Tsuneda S; Komatsu N
    PLoS One; 2015; 10(3):e0122003. PubMed ID: 25794279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].
    Fan Z; Zhang R; Shen YM; Fei HR; Zhu ZL; Cen JN
    Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):611-4. PubMed ID: 19175989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.